AMED Stock Recent News

Amedisys (AMED) came out with quarterly earnings of $0.94 per share, missing the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.16 per share a year ago.

Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?

Amedisys, Inc. is set to be acquired by UnitedHealth Group in a $3.29 billion merger agreement. Some US legislators have called for further scrutiny of the merger, citing concerns of increased market dominance and higher medical costs. UnitedHealth's subsidiary, Optum Group, has been expanding its service provision through acquisitions, including a recent deal with UK health-tech company EMIS Group.

Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amedisys (AMED) came out with quarterly earnings of $0.98 per share, missing the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.15 per share a year ago.

Here is how Amedisys (AMED) and Cybin Inc. (CYBN) have performed compared to their sector so far this year.

Strength in Hugh Acuity Care segment and Hospice division drive Amedisys (AMED) Q2 performance.

While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

The Dow Jones Industrial Average fell 1.1%, or 366 points, Thursday after private sector payroll data showed that the labor market remains strong, raising fears that the Federal Reserve could hike rates faster or higher than planned.